The same glass can be said to be half full or half empty. This is now the case with the treatment of short stature caused by dyschondrosteosis with growth hormone alone. The recent article by Dantas et al adds to the studies by Blum et al [2,3], and Bennabad et al [4] to give a very coherent view of the results of this treatment. Dantas et al provide an interesting explanation for this mitigated result. Indeed, over the years of treatment, the annual growth rate, which reached 8.5 cm on average in the 1st year, progressively decreased to 5.3 cm in the 4th year. This decrease parallels that of the circulating IGF1. Almost all of the height gain occurred in the first year of treatment. Clearly, the same dose of growth hormone per kg of body weight, sees its effects decrease inexorably over time, which reflects a progressive secondary resistance to growth hormone. In view of this, it can be assumed that adjusting twice yearly the dose of growth hormone in proportion to the resistance that develops would lead to better results.


中文翻译：

---

GH治疗软骨病的半空杯

同一个杯子可以说是半满或半空。现在，仅用生长激素治疗由软骨骨发育不良引起的身材矮小就是这种情况。Dantas 等人最近的文章补充了 Blum 等人 [2,3] 和 Bennabad 等人 [4] 的研究，对这种治疗的结果给出了非常一致的看法。Dantas 等人为这种缓解结果提供了一个有趣的解释。事实上，经过多年的治疗，第 1 年平均达到 8.5 厘米的年增长率逐渐下降到第 4 年的 5.3 厘米。这种减少与循环 IGF1 的减少相似。几乎所有的身高增加都发生在治疗的第一年。显然，每公斤体重使用相同剂量的生长激素，其效果会随着时间的推移而无情地减弱，这反映了对生长激素的进行性继发性抗性。鉴于此，可以假设每年两次根据所产生的抗性调整生长激素的剂量会导致更好的结果。